Rosetta Capital
Rosetta Capital Limited is a UK life-sciences and medical-device venture capital firm incorporated in 2000 (originally Bioscience Managers Limited) and headquartered in Haddenham, Buckinghamshire. Authorised and regulated by the Financial Conduct Authority (FRN 196844), it invests globally through direct secondary transactions, acquiring baskets of late-stage therapeutic, diagnostic and medical-device assets from venture funds, corporates and listed trusts seeking liquidity. Over 20-plus years the firm has completed 50-plus venture investments and currently manages Funds IV and V.
Key facts
Recent exits
Coverage notes
2 funds tracked, 19 portfolio companies (17 active · 2 realized). Verified weekly from public filings and deal announcements.
Funds & portfolio
Every fund Rosetta Capital has raised, with its portfolio companies. Hand-checked from public filings.
Rosetta Capital VSecondaries2021 · 5yr€57M7 active
Unrealized
7 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Carrick Therapeutics | Biotech | Ireland | 2021 |
| Immunocore | Biotech | UK | 2021 |
| Inivata | HealthTech | UK | 2021 |
| Mereo BioPharma | Biotech | UK | 2021 |
| Mission Therapeutics | Biotech | UK | 2021 |
| PsiOxus Therapeutics | Biotech | UK | 2021 |
| ReNeuron | Biotech | UK | 2021 |
Rosetta Capital IVSecondaries2013 · 13yr€30M10 active · 2 realized
Unrealized
10 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Akinion Pharmaceuticals | Pharma | Sweden | 2013 |
| Axelar | Biotech | Sweden | 2013 |
| Clanotech | Biotech | Sweden | 2013 |
| Dilafor | Biotech | Sweden | 2013 |
| Inhalation Sciences | MedTech | Sweden | 2013 |
| NeoDynamics | MedTech | Sweden | 2013 |
| NovaSAID | Biotech | Sweden | 2013 |
| Pergamum | Biotech | Sweden | 2013 |
| Promimic | MedTech | Sweden | 2013 |
| Umecrine Mood | Biotech | Sweden | 2013 |
Realized
2 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| Aprea Therapeutics | Biotech | Sweden | 2013 | 2019 | IPO | – | – |
| Biosergen | Biotech | Sweden | 2013 | 2021 | IPO | – | – |
Saved GPs appear in your watchlist, one click from your workspace.
About Rosetta Capital
Rosetta Capital is an alternative investment platform with capital deployed across 1 active fund vehicles, headquartered in London. The firm deploys capital across European mid and small-cap businesses spanning software, consumer, TMT, financials, healthcare and business services.
Investment thesis
The platform combines complementary investment strategies, deploying capital across software, consumer, TMT, financials, healthcare and business services businesses in the United Kingdom and broader European market. Multi-strategy capital deployment enables flexibility across the business lifecycle, with the partnership culture supporting management teams through growth, transmission and selective M&A across multiple fund vintages and asset classes.
Recent activity
Realised exits across the current platform vintages remain limited, with the portfolio in active deployment and value-creation phase. The platform tracks 1 dedicated investment vehicle, 15 active portfolio companies and 0 realised exits across the strategy's history. Detailed buyer names and multiple data available on Pro at €29/month.
Similar firms
Other private equity firms tracked on GP Intel.
United Kingdom·€309.0BUnited Kingdom·€15.4BUnited Kingdom·€12.7BUnited Kingdom·€11.7BUnited Kingdom·€6.4BUnited Kingdom·€4.1BUnited Kingdom·€3.5BUnited Kingdom·€2.3BUnited Kingdom·€2.3BUnited Kingdom·€1.8BUnited Kingdom·€1.8BUnited Kingdom·€1.6B